NEW YORK, January 14, 2015 /PRNewswire/ --
Moments ago, Analysts Review released new research updates concerning several important developing situations including Acorda (NASDAQ: ACOR), Acura Pharmaceuticals (NASDAQ: ACUR), Adamas (NASDAQ: ADMS), Adamis (NASDAQ: ADMP), and Addus HomeCare (NASDAQ: ADUS). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
To access our full PDF reports on a complementary basis, please visit the links below.
Today's update concerns the following companies:
Full PDF Download Links (you may have to copy and paste the following links into your browser):
ACOR Research Report: ( http://get.analystsreview.com/pdf/?c=Acorda&d=14-Jan-2015&s=ACOR ),
ACUR Research Report: ( http://get.analystsreview.com/pdf/?c=Acura%20Pharmaceuticals&d=14-Jan-2015&s=ACUR ),
ADMS Research Report: ( http://get.analystsreview.com/pdf/?c=Adamas&d=14-Jan-2015&s=ADMS ),
ADMP Research Report: ( http://get.analystsreview.com/pdf/?c=Adamis&d=14-Jan-2015&s=ADMP ),
ADUS Research Report: ( http://get.analystsreview.com/pdf/?c=Addus%20HomeCare&d=14-Jan-2015&s=ADUS ).
Analyst Update: Clinical Trials, Drug Distribution, Milestone Payments, Appointments and Acquisitions
Reviewed by: Rohit Tuli, CFA®
Volatility gripped the U.S. market on Tuesday as the Dow Jones Industrial Average, which vaulted over 282 points during the session, erased all the gains and slipped into negative territory, led by a decline in materials and energy shares. The U.S. stocks fluctuated between gains and losses during the session, mirroring the movement in oil prices which tumbled to near six-year lows before recovering. The Dow Jones Industrial Average ended the session 0.15% lower at 17,613.68, the S&P 500 lost 0.26% to close at 2,023.03, and the Nasdaq Composite dropped 0.07% to 4,661.50. Meanwhile, European shares rose for the second consecutive session on Tuesday, helped by rally in retail stocks and data showing that U.K. inflation fell to the lowest level in 15 years. Most of the Asian markets also ended lower on Tuesday as continued drop in the prices of oil turned investors cautious towards risky assets.
With the enrollment of the first patient, Acorda Therapeutics, Inc. (Acorda) has initiated the Phase 3 clinical trial of Dalfampridine for the treatment of post-stroke walking deficits (PSWD). This multi-center, double-blind, randomized trial is expected to enroll c.540 participants who have undergone an ischemic stroke at least six months prior to enrollment.
Acura Pharmaceuticals, Inc. (Acura Pharmaceuticals) has acknowledged Kmart Pharmacy for the distribution of NEXAFED [pseudoephedrine hydrochloride (HCl)], a 30 mg immediate-release abuse-deterrent decongestant.
Adamas Pharmaceuticals, Inc. (Adamas) announced that, on the basis of the recent FDA approval of Namzaric™, formerly known as MDX-8704, the Company has received a $30 million milestone payment from Forest Laboratories Holdings Limited, a subsidiary of Actavis plc.
Adamis Pharmaceuticals Corporation (Adamis) has announced key additions to its medical and product marketing management teams for further development of its product pipeline. Furthermore, the new appointments would assist in preparation of a sales and marketing plan for the anticipated launch of Company's epinephrine pre-filled syringe for treatment of allergic reactions (Type I) including anaphylaxis.
Addus HomeCare Corporation (Addus HomeCare) on January 1, 2015 acquired Priority Home Health Care, Inc., thus expanding its presence in the state of Ohio. The Company anticipates the transaction to be accretive to earnings in 2015. Headquartered in Cleveland, Ohio, Priority Home Health operates six offices in the Cleveland, Akron and Columbus areas, which are expected to produce revenues of c.$11 million for the year ended December 31, 2014.
About Analysts Review
At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.
Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA®. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review